ProCE Banner Activity

LINKER-MM1 Update: Phase I/II Trial of Anti-BCMAxCD3 Bispecific Antibody Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Conference Coverage
Slideset

Longer-term follow-up of the LINKER-MM1 trial of linvoseltamab 200 mg in patients with previously treated MM demonstrated deepening response over time with a manageable safety profile.

Released: December 14, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.